Omniab, Inc. cash flow statement
In fiscal 2025, Omniab, Inc.'s operations generated −$36.5m of cash; it spent $565,000 on capital projects, leaving free cash flow of −$37.0m.
Cash flow statement
| Fiscal year | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | −6 | −4 | 2 | −40 | −36 | 3 |
| Depreciation and amortisation | 16 | 18 | 19 | 24 | 22 | 9 |
| Stock-based pay | 15 | 18 | 25 | 21 | 16 | 13 |
| Capital spending | 4 | 17 | 2 | 2 | 1 | 0 |
| Free cash flow | −10 | −21 | 1 | −42 | −37 | 2 |
| Free cash flow after stock pay | −25 | −39 | −24 | −63 | −53 | −11 |
| Shares issued | 0 | 96 | 0 | 11 | 0 | — |
| Quarter | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 | 2026 Q3Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −4 | −16 | −5 | −10 | −6 | −5 | 3 | 11 |
| Depreciation and amortisation | 8 | 5 | 1 | 1 | 8 | 1 | 1 | 1 |
| Stock-based pay | 5 | 4 | 4 | 4 | 4 | 3 | 3 | 3 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −4 | −16 | −5 | −10 | −6 | −5 | 3 | 11 |
| Free cash flow after stock pay | −9 | −20 | −9 | −14 | −9 | −8 | −1 | 8 |
| Shares issued | 3 | — | — | — | 0 | — | — | — |
Compare with peers
- Alpha Teknova, Inc. cash flow
- Rapid Micro Biosystems, Inc. cash flow
- Maxcyte, Inc. cash flow
- Bionano Genomics, Inc. cash flow
- Champions Oncology, Inc. cash flow
Head to head: OABI vs TKNOOABI vs RPIDMXCT vs OABIBNGO vs OABI
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies